ITEMS IN AFP WITH KEYWORD:
May 1, 2016 Issue
Alpha-Lipoic Acid for Treatment of Diabetic Peripheral Neuropathy [FPIN's Help Desk Answers]
Intravenous (IV) ALA can improve neuropathy symptoms when administered for three weeks, but symptom improvement with oral ALA is not clinically significant. There is no evidence evaluating long-term treatment.
In this group of older patients (mean age = 68 years) who do not have diabetes but are at high risk of cardiovascular disease, a more aggressive systolic BP target of 120 mm Hg instead of 140 mm Hg led to benefits (lower all-cause mortality, lower cardiovascular mortality, less heart failure), but a...
In patients with established CV disease and type 2 diabetes, the addition of empagliflozin to standard therapy reduces all-cause mortality and CV mortality. This is notable because empagliflozin is the only drug other than metformin to demonstrate a mortality benefit, albeit for a fairly narrow group of patients.
The American Heart Association (AHA) and American Diabetes Association (ADA) joined together to release statements on preventing CVD in persons with diabetes.
Review key screening recommendations for type 2 diabetes in nonpregnant adults, pregnant women, children, and older persons. Learn which test results are considered diagnostic.
Jan 15, 2016 Issue
Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus: Recommendation Statement [U.S. Preventive Services Task Force]
The USPSTF recommends screening for abnormal blood glucose as part of cardiovascular risk assessment in adults aged 40 to 70 years who are overweight or obese. Clinicians should offer or refer patients with abnormal blood glucose to intensive behavioral counseling interventions to promote a healthful diet and physical activity.
The glass half full is that sitagliptin does not increase the risk of cardiovascular events in patients with type 2 diabetes. The glass half empty is that it does not reduce the risk, either. And that is the important message: In patients with a mean glycated hemoglobin level of 7.2%, adding sitagli...
Clinicians need to consider the best available research findings, their own experience, and their patients' needs and values.
Review the key components of diabetes treatment, including nutrition, exercise, and pharmacologic therapies. Metformin is the first-line choice of hypoglycemic agents to reduce mortality and complications. Learn which A1C goals are most appropriate for patients.
Dapagliflozin will lower A1C levels by an average of 0.7 percentage points when used alone or by an average of 0.5 percentage points when added to metformin therapy. Its effect on diabetes-associated morbidity and mortality has not been studied, and although it is well tolerated, there is an associa...